Pfizer Collaborates with Arvinas for Breast Cancer Therapy
By Shikha Kashyap
Pharma Deals Review: Vol 2021 Issue 8 (Table of Contents)
Published: 20 Aug-2021
DOI: 10.3833/pdr.v2021.i8.2634 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Strengthening its commitment to oncology, Pfizer has entered into a collaboration with Arvinas to develop and commercialise an investigational oral proteolysis targeting chimera (PROTAC) oestrogen receptor protein degrader, ARV-471, for the treatment of breast cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS